Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Historical Holders from Q3 2018 to Q4 2025

Symbol
CRNX on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
94,179,674
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
107,699,166
Holdings value
$4,485,877,349
% of all portfolios
0%
Number of holders
223
Number of buys
122
Number of sells
108
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +46% $468,126,802 +$145,081,664 13,957,269 +45% FMR LLC 31 Mar 2025
VANGUARD GROUP INC 10% +2% $312,311,064 +$7,452,890 9,311,600 +2.4% The Vanguard Group 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 8.9% +45% $349,109,925 +$107,235,547 8,381,991 +44% Wellington Management Group LLP 30 Sep 2025
Farallon Capital Partners, L.P. 6% $165,377,881 5,625,098 Dapice Joshua J. 29 Aug 2025
As of 30 Sep 2025 Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) has 223 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 107,699,166 shares of the company stock as of 30 Sep 2025.

Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 7,500 $349,413 +$338,567 $46.57 2
2025 Q3 107,699,166 $4,485,877,349 +$149,678,944 $41.65 223
2025 Q2 104,559,713 $3,007,383,972 +$75,026,428 $28.76 220
2025 Q1 101,790,251 $3,418,300,735 +$9,854,245 $33.54 224
2024 Q4 99,674,221 $5,096,189,681 +$758,216,412 $51.13 244
2024 Q3 84,507,337 $4,321,028,203 +$33,462,820 $51.10 232
2024 Q2 82,467,822 $3,693,699,265 +$92,226,194 $44.79 232
2024 Q1 80,359,899 $3,761,530,071 +$489,176,945 $46.81 202
2023 Q4 80,689 $2,870,914 -$1,386,175 $35.58 2
2023 Q3 68,511,875 $2,037,425,662 +$442,722,141 $29.74 169
2023 Q2 53,863,376 $970,580,866 -$14,285,261 $18.02 136
2023 Q1 55,022,720 $883,667,022 +$108,684 $16.06 126
2022 Q4 54,774,480 $1,002,337,337 -$29,154,494 $18.30 118
2022 Q3 51,383,891 $1,009,393,441 +$12,479,930 $19.64 113
2022 Q2 50,481,358 $941,464,132 +$94,025,834 $18.65 106
2022 Q1 45,457,476 $996,878,431 +$24,817,290 $21.95 111
2021 Q4 44,253,023 $1,255,973,441 +$251,348,520 $28.41 112
2021 Q3 33,618,331 $707,848,662 +$17,128,111 $21.05 91
2021 Q2 32,726,927 $616,934,642 +$43,330,866 $18.85 81
2021 Q1 30,663,471 $464,249,247 +$5,703,309 $15.28 77
2020 Q4 30,426,213 $429,299,885 -$4,585,138 $14.11 84
2020 Q3 30,337,604 $475,397,972 -$19,900,631 $15.67 70
2020 Q2 31,442,275 $545,926,663 +$188,615,966 $17.52 78
2020 Q1 20,679,259 $303,859,789 +$45,414,739 $14.70 54
2019 Q4 17,522,474 $439,633,847 -$5,476,517 $25.09 57
2019 Q3 15,234,699 $229,128,583 -$94,249,206 $15.04 60
2019 Q2 15,309,756 $382,744,098 +$30,946,837 $25.00 61
2019 Q1 17,728,104 $403,489,060 +$21,013,334 $22.76 61
2018 Q4 16,774,198 $503,053,000 +$19,132,463 $29.99 48
2018 Q3 16,164,854 $463,123,000 +$463,123,123 $28.65 48